JP-1366
Phase 3Small molecule
JP-1366 is one of 102 small molecule programs targeting Gastric Ulcer. It is currently in Phase 3.
4
Indications
9
Total Trials
2
Active Trials
101
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
80 competitors in Gastroesophageal Reflux Disease
#DrugCompanyPhaseTrials
1Prilosec
DDexcel Pharma Technologies Ltd.
Approved
Prevacid
TakedaPhase 3
Rabeprazole ER
EisaiPhase 3
Zantac 150
CChattem
Phase 3
Pulmicort
SSalix
Phase 3
Esomeprazole Mg
AstraZenecaPhase 3
Circadin
NNeurim Pharmaceuticals Ltd.
Phase 3
DWP14012
Daewoong Pharmaceutical Co. LTD.Phase 3
Domperidone
Johnson & JohnsonPhase 3
Lioresal
NovartisPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Clinical Trial2 trials
Drug Interactions1 trial
Atorvastatin1 trial
Gastroesophageal Reflux Disease1 trial
3 more indications
Peptic ulcer1 trial
Gastric Ulcer1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for JP-1366. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- OOnconic Therapeutics Inc.